VALIDATE Annual Meeting 2024 - Provisional Agenda

Please note that this is a Provisional Agenda and is subject to change. Applications for our latest rounds of Fellowships are still open, and we will be in touch with details of their talks as soon as they are selected.

 

Day One - Tuesday, 16 July 2024

 

 

0900 - 1000    Closed Network Management Board (NMB) & Scientific Advisory Board (SAB) Meeting  (Invitation only)

0915 - 1000    Registration & Tea/Coffee 

 

1000 – 1015    Welcome

Prof Helen McShane, VALIDATE Network Director, University of Oxford, UK & Prof Narisara Chantratita, Mahidol University, Thailand

 

 

1015 – 1035    VALIDATE Update

Mrs Samantha Vermaak, Co-Investigator & Executive Manager, University of Oxford, UK

 

 

1035 – 1120    Navigating the Landscape: Understanding Melioidosis through Clinical Epidemiology, Immune Response Dynamics, and Diagnostic Innovations

Prof Narisara Chantratita, Mahidol University, Thailand

 

 

1120 – 1140    Identifying Persister Mycobacterium tuberculosis Biosignatures

Dr Nastassja Kriel, Stellenbosch University, South Africa

 

 

1140 – 1200    Evaluation of the Efficacy of BCGΔBCG1419c Vaccination Plus a Booster of EsxG/EsxH-derived Peptides to Prevent Tuberculosis Progression 

Dr Cristian Segura-Cerda, Centro de Investigación y Asistencia en Tecnología y Diseño de Jalisco (CIATEJ), Mexico

 

 

1200 – 1300        Lunch

 

1300 – 1330   Different Adjuvants Significantly Influence the Immunogenicity and Protective Capacity of a Melioidosis Subunit Vaccine

Prof Mary Burtnick, University of Nevada, Reno School of Medicine, USA

 

 

1330 – 1350 Alvacc A Human In Vitro Alveolus Model to Study Aerogenic TB Vaccine Binding and Translocation

Dr Diane Lee, University of Surrey, UK

 

 

1350 – 1410    Towards a T-cell Subset that can Control Mycobacterium tuberculosis Infection

Dr Munyaradzi Musvosvi, University of Cape Town (UCT), South Africa

 

 

1410 – 1430    Evaluation of BCGΔBCG1419cESAT6-PE25SS in Immunocompetent and Immunocompromised Mouse Models of TB  

Dr Ana Maria Valencia-Hernandez, James Cook University, Australia

 

 

1430 – 1500    The Deletion of Interleukin-4 receptor alpha (IL-4Rα) Signalling on T cells Increased Host Susceptibility to TB
Dr Suraj Parihar, University of Cape Town (UCT), South Africa

 

 

1500 – 1530    Afternoon Break

 

1530 – 1600    Therapeutics Informing Vaccine Development for Human Leishmaniasis

Dr Maria Adelaida Gomez, Centro Internacional de Entrenamiento e Investigaciones Medicas (CIDEIM), Colombia

 

 

1600 – 1645    Talks from New VALIDATE Fellows - Titles, abstracts, and speakers to be confirmed soon

 

 

 

1645 – 1700    Day Wrap up

1700 – 1850    Drinks Reception / Poster Session

1850 – 2120    Annual Meeting Dinner

Day Two - Wednesday, 17 July 2024

 

0900 – 0945    Lessons Learned in BP vs NTM Research

Asst Prof Ganjana Lertmemongkolchai, Chiang Mai University, Thailand

 

 

0945 – 1030    Talks from New VALIDATE Fellows - Titles, abstracts, and speakers to be confirmed soon

 

 

 

1030 – 1100    “Mind the Gap” – Bridging Our Knowledge of Animal and Human Tuberculosis

Prof Michele Miller, Stellenbosch University, South Africa

 

 

1100 – 1130    Morning Break

 

1130 – 1145    Innovative Diagnosis for PKDL/Leprosy Project Update 

Prof Mitali Chatterjee, Institute of Post-Graduate Medical Education and Research (IPGMER), India

 

 

1145 – 1205    Towards a Better TB Vaccine Understanding Improved Local Immune Control by Mucosal BCG Vaccination

Dr Paula Niewold, Leiden University Medical Center (LUMC), Netherlands

 

 

1205 – 1225    Testing a Novel, Self-adjuvanting Mucosal Vaccine Candidate for TB in the Mouse Model of Infection 

Dr Andy Tran, St George’s University of London (SGUL), UK

 

 

1225 – 1245    Characterising the Cytokines Associated with Trained Innate Immunity in BCG Vaccinated Non-human Primates

Dr Laura Sibley, UK Health Security Agency (UKHSA), UK

 

 

1245 - 1345    Lunch

 

 

 

1345 – 1415    Speaker TBC

 

 

 

1415 – 1500    Talks from New VALIDATE Fellows - Titles, abstracts, and speakers to be confirmed soon

 

 

1500 – 1530    Afternoon Break

 

1530 – 1600    Defining Correlates of Humoral Immunity Against Inhalational Melioidosis

Prof Paul Brett, University of Nevada, USA;

 

 

1600– 1630    Planning Phase I and Phase II vaccine trials: lessons from the past 30 years of human vaccine trials

 

Honorary Professor Allan Saul, The Burnet Institute / University of Melbourne, Australia

 

 

 

1630– 1645    Wrap-up and farewell